MDD
Overview of Major Depressive Disorder (MDD) in the United States
Total Population Context: Approximately people in the United States.
Demographic Focus: Individuals aged and older exhibit significant prevalence, specifically targeting adults aged to .
Prevalence Statistics:
Approximately in Americans report symptoms of depression.
of women utilize prescription antidepressants.
Economic and Social Impact:
MDD is ranked on the global disability list.
The total economic burden of MDD is estimated at .
Clinical Characterization and Definition
Verbatim Definition: MDD is a "debilitating disease that is characterized by at least one discrete depressive episode lasting at least and involving clear-cut changes in mood, interests and pleasure, changes in cognition and vegetative symptoms."
Symptom Clustering: The symptoms characterizing a major depressive episode in MDD significantly overlap with the depressive symptoms observed in Schizophrenia and Bipolar Disorder.
Disability and Suicide Risk:
There is a high risk of disability associated with the disorder.
Suicide Statistics: Of the suicides occurring annually worldwide, approximately occur during a depressive episode.
Patients diagnosed with MDD are almost -fold more likely to die by suicide compared to the general population.
Determinants of Major Depressive Disorder
Environmental Determinants (Consistent in both Men and Women):
Absence of a partner (due to factors such as divorce or widowhood).
Recent negative life events, including illness, the loss of close relatives or friends, financial problems, social problems, and unemployment.
Social Determinants:
Childhood Adversities: These are linked to higher symptom severity, a poorer disease course, and a higher rate of treatment non-response.
Socioeconomic Factors: Low socioeconomic status, low social support, and low educational attainment are key risk factors.
Disease Course and Prognosis
Predictors of Course: Higher symptom severity, psychiatric comorbidity, and a history of childhood trauma predict a less favorable disease course.
Population-Based Samples:
The mean duration of a single episode varies between and .
Approximately to of patients recover within .
Outpatient Care Settings (Less Favorable):
Only of patients achieve remission within .
Greater than of patients still meet the criteria for MDD after .
Remission and Recurrence:
Residual symptoms and functional impairments often persist even after remission.
of patients who achieve remittance will experience at least one recurrence during their lifetime.
Pathophysiology: Genetics and Environment
Genetic Factors:
First-degree relatives of MDD patients have a -fold increased risk of developing the disorder.
Heritability is quantified at approximately .
Genetic overlap exists with Schizophrenia and Bipolar Disorder.
The risk is highly polygenic, involving many genes that each contribute small effects.
Environmental Factors in Adulthood: Stressful events in the year preceding onset, such as loss of employment, financial insecurity, chronic or life-threatening health problems, exposure to violence, and separation.
Childhood Antecedents: Exposure to physical abuse, sexual abuse, and psychological neglect significantly increases the risk of later MDD.
Pathophysiology: HPA Axis and Neuroinflammation
Hypothalamic-Pituitary Axis (HPA): Early-life stress produces persistent increases in the activity of Corticotropin-Releasing Hormone (CRH)-containing neural circuits.
Clinical Studies on Abuse: Adults who experienced childhood sexual or physical abuse show markedly enhanced HPA axis activity when exposed to psychosocial stressors or endocrine tests designed to suppress HPA activity.
Glucocorticoid Resistance:
Glucocorticoid receptor function is reduced in these individuals.
Reduced receptor function leads to increased activation of the inflammatory system, which is normally under the physiological inhibitory control of cortisol.
Pathological triad: Glucocorticoid resistance, HPA axis hyperactivity, and increased inflammation are all evident in MDD.
Pathophysiology: Structural Brain Changes
MRI Findings: Structural MRI studies indicate that patients with MDD, compared to healthy controls, exhibit smaller brain volumes in the following regions:
Basal Ganglia
Thalamus
Hippocampus
Orbitofrontal Cortex
Psychotherapy Modalities
Cognitive-Behavioral Therapy (CBT): Focuses on teaching the patient to identify negative, distorted thinking patterns and provides skills to test and challenge these thoughts, replacing them with accurate positive ones.
Behavioral Activation Therapy: Focuses on increasing activities that provide pleasure or mastery and addresses avoidance processes.
Psychodynamic Therapy: Explores how emotions, thoughts, and early life experiences have created patterns contributing to current problems.
Problem-Solving Therapy: Teaches a structured set of skills to generate creative solutions for problems, overcome barriers, and make effective decisions.
Interpersonal Therapy: Helps patients resolve problems in relationships and social roles, such as conflicts, transitions, or relationship impoverishment.
Mindfulness-Based Therapy: Based on contemplative practices (primarily Buddhism); involves non-judgmental acceptance of thoughts and feelings through regular meditative practice.
Pharmacotherapy and Mechanism of Action
Classic Treatment Goal: Increasing monoamine levels in the brain.
Drug Classes and Examples:
Tricyclic Antidepressants (TCAs): Amitriptyline, Imipramine, Desipramine, Nortriptyline, Clomipramine, Trimipramine, Doxepin.
Selective Serotonin Reuptake Inhibitors (SSRIs): Sertraline, Fluoxetine, Paroxetine, Citalopram, Escitalopram, Fluvoxamine.
Selective Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine, Duloxetine, Milnacipran, Desvenlafaxine, Levomilnacipran.
Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Moclobemide.
Others/Multimodal: Vortioxetine, Vilazodone, Trazodone, Agomelatine, Mirtazapine, Mianserin, Reboxetine, Bupropion.
Neurotransmission Targets and Receptor Interactions
Transporters:
Serotonin Transporter (5-HTT): Targeted by Vortioxetine, Vilazodone, SSRIs, SNRIs, and TCAs.
Noradrenaline Transporter: Targeted by Reboxetine, Bupropion, SNRIs, and TCAs.
Dopamine Transporter: Targeted by Bupropion.
Presynaptic Targets:
MAO Enzyme: Inhibited by Phenelzine, Tranylcypromine, and Moclobemide.
Autoreceptor: Targeted by Vilazodone.
Autoreceptor: Targeted by Vortioxetine.
Postsynaptic and Diverse Receptors:
Receptors: Targeted by Trazodone, Agomelatine, Mirtazapine, Amitriptyline, Doxepin, and Mianserin.
-adrenergic and -adrenergic Receptors: Targeted by TCAs, Trazodone, Mirtazapine, and Mianserin.
(Histamine) Receptor: Targeted by Mirtazapine and Mianserin.
Muscarinic Acetylcholine Receptors: Targeted by TCAs (Amitriptyline, Clomipramine, Trimipramine, Doxepin).